Industry FDA · ICH GCP · 21 CFR Part 11 — verified scientific reasoning with full audit trails. Request Access →
Pharma & Life Sciences · Research Intelligence

The polished wrong answer
is more dangerous than no answer.

Multi-step scientific reasoning, formula discovery, drug interaction analysis, and research verification — with a complete proof chain on every result. Built for the environments where confident-but-wrong is the failure mode LLMs are hardwired for.

Request Access Talk to the team
FDA · ICH GCP · 21 CFR PART 11 · VERIFIED SCIENTIFIC REASONING · FULL AUDIT TRAIL · NO HALLUCINATIONS · CROSS-DOMAIN DISCOVERY · ON-PREMISE · DATA NEVER LEAVES · FDA · ICH GCP · 21 CFR PART 11 · VERIFIED SCIENTIFIC REASONING · FULL AUDIT TRAIL · NO HALLUCINATIONS · CROSS-DOMAIN DISCOVERY · ON-PREMISE · DATA NEVER LEAVES ·

Scientific truth is not
a language pattern.

LLMs are extraordinarily good at producing text that sounds like scientific reasoning. They are structurally incapable of producing scientific reasoning. In drug discovery, clinical research, and regulatory submission, the difference between a fluent wrong answer and a correct one is not a style question — it is a patient safety question.

Research Integrity

Hallucinated citations end careers and research programs.

A confident fabrication about a study that doesn't exist, a mechanism that hasn't been demonstrated, or an interaction that hasn't been characterized is not a minor error in pharma research. It is a reproducibility failure, a regulatory risk, and potentially a patient safety event. Helixor cites what exists and refuses to produce what doesn't.

Regulatory Submission

FDA audit trails require the actual reasoning, not a reconstruction.

21 CFR Part 11 and ICH GCP require that electronic records and their underlying reasoning be auditable and reproducible. Post-hoc explanations generated by a language model do not satisfy this requirement. Helixor's structured proof chain is produced by the same execution that generated the result — it is the actual reasoning, not a description of it.

Proprietary Data

Compound structures, trial data, and genomic sequences cannot leave the facility.

Sending proprietary compound structures, unpublished trial data, or genomic sequences to a cloud inference endpoint for every query is not a data governance issue to be managed with a BAA. It is a competitive and regulatory exposure that compounds with every query. Helixor runs on-premise, processes data locally, and makes no external calls.

Cross-Domain Discovery

The most valuable insights in research come from unexpected domain crossings.

The mechanism that explains a crop yield response may also explain a cellular receptor interaction. The statistical pattern in orbital mechanics may describe protein folding behavior. Helixor's cross-domain reasoning architecture finds these structural similarities — transferring verified knowledge patterns across domains rather than searching within them.

From hypothesis to verified result.
With proof at every step.

01 · Formula Discovery

Automated discovery of mathematically verified formulas.

Evolutionary search through mathematical transformation space — discovering relationships between variables that aren't apparent from first principles. Every discovered formula is verified before it is returned. No candidate that cannot be proven is presented as a result.

02 · Drug Interaction Analysis

Verified interaction reasoning across known mechanisms.

Multi-step reasoning across pharmacological constraint chains — identifying interaction risks, contraindication patterns, and mechanism overlaps with a structured proof chain on every conclusion. Every output is traceable to its source evidence, not generated from statistical co-occurrence.

03 · Clinical Trial Optimization

Protocol design and cohort planning as a constraint problem.

Inclusion/exclusion criteria, endpoint selection, site allocation, and statistical power requirements — optimized simultaneously as a unified constraint problem. Replanned in real time as enrollment data and interim results arrive, with full constraint enforcement on every protocol modification.

04 · Cross-Domain Transfer

Knowledge patterns that jump domain boundaries.

Verified mathematical relationships from physics, ecology, or materials science transferred to biological, pharmacological, or genomic contexts — where the underlying structure is similar even when the domain vocabulary is entirely different. Every transfer is validated before it becomes a hypothesis.

05 · Regulatory Documentation

Submission-ready audit trails generated automatically.

Every analytical decision, model output, and reasoning step structured and logged with the provenance required for FDA submission and ICH GCP compliance. The audit trail is an output of the process — not a documentation task performed after it.

06 · Research Knowledge Base

Evidence-grounded answers with citation on every query.

Internal research documents, published literature, and proprietary experimental data — indexed and queried with source attribution and confidence scoring. Every answer includes the provenance of its evidence. "Unknown" when evidence is insufficient. Never a fabrication.

Hypotheses evaluated.
Results verified. Continuously.

Helixor continuously evaluates incoming research queries, incoming data signals, and hypothesis candidates — returning verified results or explicit failures, with full reasoning chains. No fabricated citations. No hallucinated mechanisms.

Helixor Research Feed — Live
--:--:--
0
Queries Processed
0
Results Verified
0
Refused (Insufficient Evidence)
0
Hallucinations

Built for the standard
scientific AI must actually meet.

Verified results
or explicit refusal.
In drug discovery and clinical research, a confident wrong answer about a compound interaction or a mechanism of action is not a minor quality issue — it is a research program risk and a potential patient safety event. Helixor's fail-closed architecture produces a verified result or an explicit statement that the evidence is insufficient. It does not generate a plausible-sounding answer when one cannot be verified.// fail-closed is not a guardrail. it is the architecture.
Cross-domain discovery
at research scale.
The most valuable discoveries in life sciences often come from recognizing that a pattern in one domain — nuclear physics, ecology, materials science — describes something in a biological or pharmacological context. Helixor's cross-domain reasoning architecture identifies these structural similarities and validates them before presenting them as candidates. Not keyword matching. Structural pattern transfer with verification.// physics → agriculture → pharmacology: verified pattern transfer, not analogy
Proprietary data stays
on your infrastructure.
Compound structures, trial data, genomic sequences, and unpublished research are among the most competitively sensitive assets in any pharma organization. Cloud AI inference requires that data to leave your infrastructure on every query. Helixor runs entirely on your hardware — making no external calls, transmitting nothing, and operating in complete isolation from external networks if required.// designed for environments with strict data residency requirements
21 CFR Part 11 audit
trail by design.
Regulatory submissions require that the reasoning behind analytical decisions be documented, reproducible, and traceable. Helixor produces a structured reasoning trace with every output — the same chain that generated the result, not a description added for compliance purposes. When the FDA asks how you got there, the answer is already in the output.// audit trail is produced by the execution, not added after it

Ready to bring verified AI
into your research pipeline?

Active conversations across pharma R&D, clinical operations, and life sciences research. Tell us where the wrong answer is the costliest.